Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ABBV-253 in Ovarian Cancer: NCT07807956 Clinical Landscape Report 2026
11 September 2026
NCT07807956 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anlotinib Dihydrochloride in EGFR-mutated non-small Cell Lung Cancer: NCT07807722 Clinical Landscape Report 2026
11 September 2026
NCT07807722 clinical landscape for EGFR-mutated non-small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
IBI3046 in Obesity: NCT07809945 Clinical Landscape Report 2026
11 September 2026
NCT07809945 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ublituximab in Myasthenia Gravis: NCT07673744 Clinical Landscape Report 2026
11 September 2026
NCT07673744 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VV169 in Relapse multiple myeloma: NCT07802717 Clinical Landscape Report 2026
11 September 2026
NCT07802717 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07701993 Clinical Landscape Report 2026
11 September 2026
NCT07701993 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Indapamide in Multiple Sclerosis, Secondary Progressive: NCT07765212 Clinical Landscape Report 2026
11 September 2026
NCT07765212 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Temozolomide in Glioblastoma Multiforme: NCT07754734 Clinical Landscape Report 2026
11 September 2026
NCT07754734 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Malignant Pleural Mesothelioma: NCT07563738 Clinical Landscape Report 2026
11 September 2026
NCT07563738 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: NCT07679893 Clinical Landscape Report 2026
11 September 2026
NCT07679893 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dexamethasone Sodium Phosphate in Uveal Melanoma: NCT07803562 Clinical Landscape Report 2026
11 September 2026
NCT07803562 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenvatinib mesylate in Hepatocellular Carcinoma: NCT07801287 Clinical Landscape Report 2026
11 September 2026
NCT07801287 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.